Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this retrospective study is to examine the outcome of patients who relapse with Ph+ ALL and to potentially identify response profiles in order toadvance the treatment regimens that can be offered.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Long term survival | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| 10 year-survival | 10 years | |
| Molecular response (BCR::ABL1 ratio) | Molecular response is assessed using BCR::ABL1 ratio, on bone marrow if available (if not, on blood) | At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patient treated by TKI
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Aline SCHMIDT, MD/PhD | Contact | 241354482 | 33 | alschmidt@chu-angers.fr |
| Véronique LHERITIER, Central coordination | Contact | 0478862239 | 33 | veronique.lheritier@chu-lyon.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| GRAALL | Recruiting | Pierre-Bénite | 69310 | France |
Not provided
Not provided
Not provided
Not provided
| Hematologic response | Hematologic response is defined by less than 5% of blasts on bone marrow aspiration | At the end of each line of treatment, at each relapse, at 5 years after the last relapse, at 10 years after the last relapse |
| Death date | Up to 10 years |
| Cause of death | Cause of death can be : 1)disease, 2)complications related to treatment except bone marrow transplant, 3)Hematopoietic Stem Cells Transplantation related, 4)other | Up to 10 years |
| Treatment characteristics (treatment name) | Name of chemotherapy or immunotherapy used | At day 1 of each new treatment of relapse |
| Treatment characteristics (treatment dates) | Start date and end date of treatment | At day 1 and at the end of each line of treatment of relapse |
| Treatment characteristics (dose) | Dose of each treatment | At day 1 of each new treatment of relapse |